Skip to main content
Premium Trial:

Request an Annual Quote

Lynx, Cue Pen Stem-Cell Gene-Expression Collaboration

NEW YORK, July 30 - Lynx Therapeutics and Cue Therapeutics today said they will collaborate to study stem-cell gene expression.


Terms of the agreement call for Lynx to apply its MPSS technology to Cue's astrocyte cells in hopes of uncovering certain factors in the maintenance of human astrocyte precursors, and perhaps also to other human stem cells.


The resulting data should serve as the groundwork for a stem-cell gene-expression database.


Click here for more information.